

Supplementary Table S1. Demographics and baseline characteristics of study subjects

<i>Patient ID</i>	<i>Age (years)</i>	<i>Sex</i>	<i>Race (Caucasian, African American, other)</i>	<i>Duration of AMD (months)</i>	<i>Prior anti-VEGF therapy</i>	<i>BCVA (letters score)</i>	<i>CST (μm)</i>	<i>Presence of intra/subretinal fluid</i>
1A	79	Male	Caucasian	34	Yes	32	474	Yes
1B	81	Female	Caucasian	47	Yes	17	716	Yes
1C	81	Female	Caucasian	— ^a	Yes	23	220	Yes
2A	84	Female	Caucasian	24	Yes	7	494	Yes
2B	79	Female	Caucasian	55	Yes	37	692	Yes
2C	88	Male	Caucasian	28	Yes	28	291	Yes
3A	95	Male	Caucasian	124	Yes	3	482	Yes
3B	70	Female	Caucasian	58	Yes	32	307	Yes
3C	64	Female	Caucasian	20	No	14	275	No
4A	63	Male	Native American	6	Yes	18	249	No
4B	64	Male	African American	57	Yes	36	179	Yes
4C	90	Female	African American	160	Yes	9	349	Yes
4D	87	Female	Caucasian	44	Yes	22	291	Yes
4E	82	Female	Caucasian	91	Yes	40	178	Yes
4F	81	Female	Caucasian	115	No	13	137	No
4G	71	Male	Caucasian	14	Yes	36	504	Yes
4H	85	Male	Caucasian	10	Yes	46	292	Yes
4I	75	Male	Caucasian	139	Yes	38	255	No
4J	80	Male	Caucasian	108	Yes	30	154	Yes
4K	80	Male	Caucasian	47	Yes	58	250	No
4L	88	Female	Caucasian	35	Yes	50	229	No

^aDisease duration not known.